GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2644089&ei=kXKaUvDOH7Hr0QGFIA&usg=AFQjCNFjn3RX0eejOaqV5Z6krjz_X6wxsg
Gilead Sciences Inc's Complera Non-Inferior To Atripla Among Treatment-Naïve HIV Patients
Thursday, 15 Nov 2012 07:01am EST
Gilead Sciences Inc announced Phase 3b clinical trial results from STaR (Single Tablet Regimen), the first head-to-head study comparing the single tablet regimens Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) and Atripla (efavirenz/ emtricitabine/tenofovir disoproxil fumarate) in treatment-naïve adults with HIV infection. Data demonstrated that Complera, which is marketed as Eviplera in the European Union, is non-inferior to Atripla based on the proportion of patients with HIV RNA levels (viral load)  100,000 copies/mL). Notably, the virologic failure rate was low and comparable between Complera and Atripla, including among patients with baseline viral load up to 500,000 copies/mL. In addition, Complera was well-tolerated with fewer adverse events across all grades and fewer discontinuations due to adverse events (3% versus 9%; p
